ATE534623T1 - 2-alkyliden-18,19-dinor-vitamin-d-verbindungen - Google Patents

2-alkyliden-18,19-dinor-vitamin-d-verbindungen

Info

Publication number
ATE534623T1
ATE534623T1 AT05722702T AT05722702T ATE534623T1 AT E534623 T1 ATE534623 T1 AT E534623T1 AT 05722702 T AT05722702 T AT 05722702T AT 05722702 T AT05722702 T AT 05722702T AT E534623 T1 ATE534623 T1 AT E534623T1
Authority
AT
Austria
Prior art keywords
compounds
activity
alkylidene
diseases
treatment
Prior art date
Application number
AT05722702T
Other languages
English (en)
Inventor
Hector Deluca
Rafal Barycki
Pawel Grzywacz
Lori Plum
Rafal Sicinski
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE534623T1 publication Critical patent/ATE534623T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT05722702T 2004-04-09 2005-02-04 2-alkyliden-18,19-dinor-vitamin-d-verbindungen ATE534623T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/821,828 US7713951B2 (en) 2004-04-09 2004-04-09 2-alkylidene-18,19-dinor-vitamin D compounds
PCT/US2005/003378 WO2005102995A1 (en) 2004-04-09 2005-02-04 2-alkylidene-18,19-dinor-vitamin d compounds

Publications (1)

Publication Number Publication Date
ATE534623T1 true ATE534623T1 (de) 2011-12-15

Family

ID=34960524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05722702T ATE534623T1 (de) 2004-04-09 2005-02-04 2-alkyliden-18,19-dinor-vitamin-d-verbindungen

Country Status (9)

Country Link
US (2) US7713951B2 (de)
EP (1) EP1735277B1 (de)
JP (1) JP4988551B2 (de)
AT (1) ATE534623T1 (de)
AU (1) AU2005235957B2 (de)
CA (1) CA2562535C (de)
MX (1) MXPA06011499A (de)
NZ (1) NZ550234A (de)
WO (1) WO2005102995A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834050B2 (en) * 2006-03-29 2010-11-16 Duke University Small molecule insulin mimetics absent quinones
JP2009533483A (ja) * 2006-04-06 2009-09-17 ウイスコンシン アラムニ リサーチ ファンデーション 2−メチレン−1α,25−ジヒドロキシ−18,19,21−トリノルビタミンD3およびその使用
MX2008012672A (es) * 2006-04-06 2008-10-15 Wisconsin Alumni Res Found Analogos de 2-metilen-1a-hidroxi-18,19,21-trinor vitamina d3 y sus usos.
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
CA2777938C (en) * 2009-10-21 2017-11-14 Wisconsin Alumni Research Foundation Method of preventing type 1 diabetes
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
EP2556054B1 (de) * 2010-03-23 2017-09-27 Wisconsin Alumni Research Foundation Diastereomere von 2-methylen-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
JP5770261B2 (ja) * 2010-03-23 2015-08-26 ウイスコンシン アラムニ リサーチ ファンデーション (20S)−2−メチレン−19−ノル−22−ジメチル−1α,25−ジヒドロキシビタミンD3および(20R)−2−メチレン−19−ノル−22−ジメチル−1α,25−ヒドロキシビタミンD3
JP5930467B2 (ja) * 2012-12-14 2016-06-08 花王株式会社 ニトリル化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3276167D1 (en) 1981-11-02 1987-06-04 Res Inst Medicine Chem Intermediates in the synthesis of vitamin d derivatives
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
GB8904154D0 (en) 1989-02-23 1989-04-05 Leo Pharm Prod Ltd Chemical compounds
US5246925A (en) * 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) * 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
NZ232734A (en) 1989-03-09 1991-11-26 Wisconsin Alumni Res Found 19-nor vitamin d derivatives and pharmaceutical compositions
AU649057B2 (en) 1990-08-24 1994-05-12 Wisconsin Alumni Research Foundation Methods and compositions containing vitamin D compounds for improvement of skin conditions
EP0474517B1 (de) 1990-09-07 1998-11-18 Wisconsin Alumni Research Foundation Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en) 1991-05-28 1994-06-30 Wisconsin Alumni Research Foundation Novel synthesis of 19-nor vitamin D compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
DE69433220T2 (de) * 1993-07-09 2004-08-19 Laboratoire Theramex Neue strukturelle Vitamin D Derivate
WO1996001811A1 (en) 1994-07-11 1996-01-25 The Johns-Hopkins University 2-substituted 1,25-dihydroxyvitamin d3 derivatives
EP0793649B1 (de) * 1994-11-21 1999-02-03 Wisconsin Alumni Research Foundation 18,19-dinor-vitamin-d-derivate
US5661140A (en) * 1994-11-21 1997-08-26 Wisconsin Alumni Research Foundation 18-nor-vitamin D compounds
US5877168A (en) * 1995-02-10 1999-03-02 Chugai Seiyaku Kabushiki Kaisha Vitamin D derivative with substituent at the 2β-position
CA2175881A1 (en) * 1995-05-09 1996-11-10 Andrzej Kutner Vitamin d compounds and methods of preparing these compounds
US5945410A (en) * 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6114317A (en) * 1998-05-21 2000-09-05 Wisconsin Alumni Research Foundation Method of locking 1α-OH of vitamin D compounds in axial orientation
US5972917A (en) * 1998-05-29 1999-10-26 Bone Care Int Inc 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof
TW396427B (en) * 1998-12-16 2000-07-01 United Microelectronics Corp Method for fabricating double gates in semiconductor
AU6527201A (en) * 2000-05-31 2001-12-11 Wisconsin Alumni Res Found 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds
CN1217664C (zh) * 2000-07-14 2005-09-07 威斯康星校友研究基金会 2-亚甲基-19-去甲-20(S)-1α,25-二羟维生素D3增加骨强度的用途
JP4022144B2 (ja) * 2000-09-08 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 1アルファ−ヒドロキシ−2−メチレン−19−ノル−ホモプレグナカルシフェロール及びその療法的適用
WO2003084925A1 (en) * 2002-03-29 2003-10-16 Wisconsin Alumni Research Foundation METHOD OF SYNTHESIZING 1α-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL
EP1559708A4 (de) * 2002-10-10 2006-07-19 Wisconsin Alumni Res Found 2,2-disubstituiertes 1a,25-dihydroxy-19-norvitamin-d-derivat
EP1613588B1 (de) * 2003-04-10 2012-05-09 Wisconsin Alumni Research Foundation 2-propyliden-19-nor-vitamin d verbindungen
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses
WO2005018658A1 (en) * 2003-08-20 2005-03-03 Wisconsin Alumni Research Foundation 2-methylene-19-nor-vitamin d2 compounds
US7214670B2 (en) * 2003-09-24 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7053075B2 (en) * 2003-11-25 2006-05-30 Deluca Hector F Methods for reducing body fat using vitamin D compounds
US8188064B2 (en) * 2003-11-25 2012-05-29 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
CA2588415C (en) * 2004-11-22 2012-07-10 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses
MX2007006544A (es) * 2004-11-22 2007-07-25 Wisconsin Alumni Res Found 2-metilen-18,19-dinor-1a-hidroxi-homopregnacalciferol y sus usos.
DK1848442T3 (da) * 2005-02-11 2012-05-29 Wisconsin Alumni Res Found 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
US7241909B2 (en) * 2005-05-03 2007-07-10 Wisconsin Alumni Research Foundation 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds

Also Published As

Publication number Publication date
US7713951B2 (en) 2010-05-11
NZ550234A (en) 2010-07-30
MXPA06011499A (es) 2007-01-16
US20100179344A1 (en) 2010-07-15
AU2005235957A1 (en) 2005-11-03
JP4988551B2 (ja) 2012-08-01
AU2005235957B2 (en) 2011-08-04
EP1735277B1 (de) 2011-11-23
US20050227950A1 (en) 2005-10-13
CA2562535A1 (en) 2005-11-03
JP2007532540A (ja) 2007-11-15
EP1735277A1 (de) 2006-12-27
WO2005102995A1 (en) 2005-11-03
CA2562535C (en) 2012-07-10

Similar Documents

Publication Publication Date Title
MXPA03000405A (es) Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos.
MXPA03000406A (es) Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
ATE556999T1 (de) 2-propyliden-19-nor-vitamin d verbindungen
Potter et al. Heterotopic ossification following combat-related trauma
DE60324909D1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta-methyl-19-nor vitamin d3 und ihre verwendung
ATE537834T1 (de) 2-methylen-19-nor-vitamin d2-verbindungen
Kunz et al. Effects of immobilization and remobilization on the ankle joint in Wistar rats
De La Mata Platelet rich plasma. A new treatment tool for the rheumatologist?
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
Giner et al. RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis
MXPA02009590A (es) Compuestos de 2-alquiliden-19-norvitamina d y sus usos terapeuticos.
ATE534623T1 (de) 2-alkyliden-18,19-dinor-vitamin-d-verbindungen
CA2403232A1 (en) 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin d compounds
MX2007006263A (es) Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos.
MX2007006261A (es) Analogos de 17,20(z)-deshidro vitamina d y sus usos.
Mombello et al. Pilon fractures: update on treatment
ATE350043T1 (de) 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen
Ferreira et al. Functional outcome of bicondylar tibial plateau fractures treated with the Ilizarov circular external fixator
WO2010006121A3 (en) 19-nor-vitamin d analogs with 3,2-dihydrofuran ring
Fatahi et al. The effect of aerobic exercise combined with bone marrow mesenchymal stem cells on inflammatory biomarkers levels of the brain in a model of osteoarthritic rat
Huang et al. Bone Marrow Mesenchymal Stem Cells Inhibits Inflammation and Promotes Chondrocyte Activity in Knee Arthritis Rats
Zhang et al. Bone Marrow Mesenchymal Stem Cells Exert Anti-Inflammatory and Chondrocyte Activity in Rats with Knee Arthritis
Chen et al. Growth Arrest Specific Gene 6 Affects Osteogenesis of Bone Marrow Mesenchymal Stem Cells in Inflammatory Environment via MAPK/AKT Signaling Pathway
Iyer The Adult Hip and Its Disorders
Xu et al. Variation of articular cartilages under abnormal stress